Ann: Half Year Report and Accounts (including Appendix 4D), page-22

Well I don't know if there is normally so much focus on doom and gloom in these, a lot of talk of the potential hurdles and pitfalls, which we all know about already TBH.

One thing that stuck out to me was that revenue from Temcell in japan actually decreased. Maybe they were doing fewer stem cell transplants and therefor had fewer cases of aGVHD, but it's still a new product, you would want to see growth in revenue at this stage.

They also haven't yet finished collecting the secondary data from the covid trial, so we will likely be waiting a while for word on whether or not Novartis is still interested.

It will be interesting to see what the result of this capital raise is, who it is going to and whether or not it will be favourable to shareholders.

At least management acknowledged that they are likely far from commercialisation and may never get there, the honesty is refreshing.

Monday or Tuesday will be interesting when they open up trading, that's for sure.